- Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2 VIRO-15 trial -

- Data demonstrate Olvi-Vec–mediated modulation of the tumor microenvironment and immune activation -

- Translational analyses identify gene expression changes associated with chemotherapy sensitization, anticancer response, and favorable prognosis following Olvi-Vec-primed immunochemotherapy treatment -

WESTLAKE VILLAGE, Calif.,, June 30, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the publication of translational and clinical findings from its Phase 1b/2 VIRO-15 trial of Olvi-Vec-primed immunochemotherapy in heavily pretreated patients with platinum-resistant/refractory ovarian cancer (PRROC). The data were presented in Gynecologic Oncology Reports, a peer-reviewed journal published by Elsevier, available here.

The publication reports data from translational analyses conducted as part of the Phase 1b/2 VIRO‑15 study in patients with PRROC, evaluating the biological effects of Olvi‑Vec on the tumor microenvironment and its impact on clinical response and survival. The clinical results are consistent with preclinical results generated by Genelux with Olvi-Vec showing in vitro viral permissivity and tumor vulnerability and the effect of Olvi-Vec primed immunochemotherapy in a mouse model of platinum-resistant ovarian cancer.